Twist Bioscience reported strong financial results with record-breaking revenues and significant gross margin improvements, driven by operational efficiencies and robust NGS performance. However, challenges in the biopharma segment and limited market impact in China were noted. Overall, the positive highlights significantly outweigh the lowlights.

Company Guidance

In the fourth quarter of 2024, Twist Bioscience surpassed its guidance across several key metrics, highlighting a significant period of financial growth and operational success. The company reported a total revenue of $84.7 million, marking a year-over-year increase of 27% and a sequential growth of 4%. Over the fiscal year, Twist achieved $313 million in revenue, reflecting a 28% rise from 2023. The gross margin for the quarter exceeded expectations at 45.1%, with the annual gross margin improving to 42.6% from the previous year's 36.6%. Additionally, the company ended the year with a robust cash position of $276.4 million. Looking forward, Twist anticipates continued growth, with fiscal 2025 revenue projected to be between $357 million to $377 million, underpinned by a targeted gross margin of approximately 48% for the year. The company also aims to achieve an adjusted EBITDA loss of $60 million to $65 million in fiscal 2025, showing a marked improvement in profitability.

Record Revenue and Growth

Twist Bioscience reported a record quarter with $84.7 million in revenue, a 27% increase year-over-year and 4% sequentially. For the year, revenue was $313 million, an increase of 28% over fiscal 2023.

Gross Margin Expansion

The company reported a gross margin of 45.1% for the quarter and 42.6% for the year, up from 36.6% in fiscal 2023, highlighting improved operational efficiency and cost management.

Strong Performance in NGS

NGS revenue for the fourth quarter grew to approximately $45.5 million, a 23% increase year-over-year, with continued sequential growth expected in the coming year.

Operational Efficiency Initiatives

Twist implemented new software and processes that doubled distribution capacity and oligo production efficiency, contributing to margin improvements.

Positive Cash Position and Strategic Partnerships

The company ended the year with $276.4 million in cash and received an additional $15 million in October from Zoma, enhancing financial stability.

---

Twist Bioscience (TWST) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TWST Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Dec 19, 2018	2018 (Q4)	- / -6.59	-0.622	-959.49% (-5.97)	―	―
Feb 07, 2019	2019 (Q1)	- / -1.18	-0.619	-90.63% (-0.56)	―	―
Apr 30, 2019	2019 (Q2)	- / -0.93	-0.617	-50.73% (-0.31)	―	―
Aug 01, 2019	2019 (Q3)	- / -0.92	-0.66	-39.39% (-0.26)	―	―
Dec 11, 2019	2019 (Q4)	- / -0.96	-6.59	85.43% (+5.63)	―	―
Feb 06, 2020	2020 (Q1)	- / -1.69	-1.18	-43.22% (-0.51)	―	―
May 07, 2020	2020 (Q2)	- / -0.85	-0.93	8.60% (+0.08)	―	―
Aug 06, 2020	2020 (Q3)	- / -0.67	-0.92	27.17% (+0.25)	―	―
Nov 23, 2020	2020 (Q4)	- / -0.54	-0.96	43.75% (+0.42)	―	―
Feb 04, 2021	2021 (Q1)	- / -0.72	-1.69	57.40% (+0.97)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

TWST Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 18, 2024	$36.89	$41.43	+12.31%
Aug 02, 2024	$53.05	$42.97	-19.00%
May 02, 2024	$32.01	$41.21	+28.74%
Feb 02, 2024	$33.26	$36.59	+10.01%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---